Skip to Content

Immune Pharmaceuticals Inc IMNPQ

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Immune Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead program, bertilimumab is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, blocking inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis and may have application in other diseases, including atopic dermatitis, asthma, and other diseases.

Contact
1 Bridge Plaza North, Suite 270
Fort Lee, NJ, 07024
T +1 201 464-2677
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2018
Fiscal Year End Dec 31, 2018
Stock Type Distressed
Employees 7